More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

S&P DJI Announces March 2022 Quarterly Rebalance

Mar 4, 2022 at 6:22 AM EST · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Mar 4, 2022 at 6:22 AM EST · 10 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2022-quarterly-rebalance-8

Neuren Pharmaceuticals Limited on 6ix

Story so far

  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021

Earlier from Neuren Pharmaceuticals

  • FDA approval for Angelman IND and Phase 2 trialFeb 24, 2022
  • 2021 Results - a transformational year for NeurenFeb 23, 2022
  • Preliminary Final Report and 2021 Full Year AccountsFeb 23, 2022
  • Notification regarding unquoted securities - NEUFeb 3, 2022
  • Q4 2021 quarterly activity and cash flow reportJan 30, 2022

Later from Neuren Pharmaceuticals

  • Ethics approval for Angelman Phase 2 trial in AustraliaMar 10, 2022
  • FDA approval for Phelan-McDermid IND and Phase 2 trialMar 22, 2022
  • FDA approval for Pitt Hopkins syndrome IND and Phase 2 trialMar 24, 2022
  • Neuren appoints Chief Medical Officer in United StatesJul 8, 2022
  • Neuren commences Phase 2 trial of NNZ-2591 in AngelmanJul 11, 2022
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer